Research presented today at SfN’s annual meeting has detailed advances in brain stimulation technologies revealing safer, more targeted means of studying brain function and treating neurological disorders.
Browsing: Cognitive/neurodegenerative disorders
Whilst at SfN’s Neuroscience 2017, Lauren Pulling sat down with Doris Doudet to hear more about her recent research, which has demonstrated elevated inflammation in the gut of a Parkinson’s disease rat model.
This review focuses on a number of melatonin hybrids resulting from the juxtaposition of tacrine, berberine, tamoxifen, curcumin, N,N-dibenzyl(N-methyl)amine, among others, with potential therapeutic effects for the treatment of neurodegenerative diseases.
Two abstracts add to evidence suggesting a negative effect of concussion on brain tissue microstructure and hippocampal function.
New insights indicate a role for the microbiome in Alzheimer’s and Parkinson’s diseases and point towards new treatment avenues.
A study supported by the National Institute on Aging has reported for the first time an association between higher glucose levels, altered glucose metabolism in the brain and Alzheimer’s pathology and symptom severity.
A lipid has caught the eye of researchers looking to help treat glaucoma and other neurodegenerative diseases.
In this #NCTalks podcast, we speak to Henrik Zetterberg; one of the world’s leading experts in fluid biomarkers for neuronal injury and degeneration.
A novel mouse model suggests brain ‘aging surge’ could be a key diagnosis period for Alzheimer’s disease, and provide new treatment possibilities.
In this research article from Future Medicinal Chemistry discover the potential of second-generation naphthyridine- and thienopyridine-based rhein–huprine hybrids in Alzheimer’s disease.